Results 141 to 150 of about 9,514 (200)

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia. [PDF]

Cancer Med
Cai Y, Rui J, Ding Z, Xie J, Jin Z, Xiao J, Xu Y.   +6 more
europepmc   +1 more source

Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents. [PDF]

Haematologica
Kayser S, Sanber K, Marconi G, Mattei A, Luskin MR, Kelkar A, Cerrano M, Kristensen DT, Roug AS, Sartor C, Giglio F, Riva M, Rizzo L, Saraceni F, Guerzoni S, Lessi F, Borlenghi E, Levis MJ, Schlenk RF, Jain T, Papayannidis C.   +20 more
europepmc   +1 more source

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. [PDF]

Exp Hematol Oncol
Zugasti I, Lopez-Guerra M, Castaño-Díez S, Esteban D, Avendaño A, Pomares H, Perez A, García-Ávila S, Conejo IP, de la Fuente Montes C, Martínez-Roca A, Merchán B, Jiménez-Vicente C, Guijarro F, Álamo JR, Cortes-Bullich A, Torrecillas V, Mont L, Carcelero E, Riu G, Zamora L, Bargay J, Triguero A, Suarez-Lledó M, Salas MQ, López-Cadenas F, Ramos F, Xicoy B, Valcárcel D, Arnan M, Martínez C, Rovira M, Fernández-Avilés F, Díez-Campelo M, Esteve J, Díaz-Beyá M.   +35 more
europepmc   +1 more source

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML. [PDF]

Blood Neoplasia
Zale AD, Sandeep Kaduluri VP, Webster JA, Levis MJ, Gojo I, DeZern AE, Ghiaur G, Gondek LP, Dalton WB, Karantanos T, Jain T, Prince GT, Jones RJ, Smith BD, Ambinder AJ.   +14 more
europepmc   +1 more source

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. [PDF]

Blood Cancer J
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C.   +28 more
europepmc   +1 more source

Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment. [PDF]

Int J Mol Sci
Simonicova K, Janotka L, Kavcova H, Borovska I, Sulova Z, Breier A, Messingerova L.   +6 more
europepmc   +1 more source

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. [PDF]

Front Med (Lausanne)
Cheng J, Fu H, Jiang L, Huang Y, Zhang Y, Long Z, Jiang X.   +6 more
europepmc   +1 more source

Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis. [PDF]

BMC Cancer
Liu Y, Zhang Y, Gao J, Wang L, Xie F, Zhang C, Mao P, Yan J.   +7 more
europepmc   +1 more source

Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax. [PDF]

J Clin Med
Palumbo FE, Duminuco A, Longo L, Vitale DC, Maugeri C, Brancati S, Parisi MS, Palumbo GA, Romano GL, Drago F, Di Raimondo F, Gozzo L, Vetro C.   +12 more
europepmc   +1 more source

Correction to "Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia". [PDF]

Cancer Med
europepmc   +1 more source